Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer

OBJECTIVE: To evaluate the safety and efficacy of cabozantinib combined with docetaxel. PATIENTS AND METHODS: This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m(2) every 3 weeks with daily prednisone 10 mg) was combined...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BJU Int
Main Authors: Madan, Ravi A., Karzai, Fatima H., Harthy, Munjid Al, Petrylak, Daniel P., Kim, Joseph W., Arlen, Philip M., Rosner, Inger, Theoret, Marc R., Cordes, Lisa, Bilusic, Marijo, Peer, Cody J., Dawson, Nancy A., Couvillon, Anna, Hankin, Amy, Williams, Moniquea, Chun, Guin, Owens, Helen, Marte, Jennifer L., Lee, Min-Jung, Tomita, Yusuke, Yuno, Akira, Trepel, Jane B., Lee, Sunmin, Steinberg, Seth M., Gulley, James L., Figg, William D., Dahut, William L.
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265825/
https://ncbi.nlm.nih.gov/pubmed/32969563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bju.15227
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki